Tests IDOV-Immune, a virus therapy, in adults with advanced solid tumors
Tests a virus treatment that may attack cancer cells in adults with advanced tumors.
Plain-language title generated from the registry record
Registry title: IDOV-Immune for Advanced Solid Tumors
Key facts
- Where
- Melbourne and Westmead, AustraliaSee the 2 sites
- Phase
- Phase 1
Where in Australia
- The Alfred HospitalMelbourne, AustraliaTaking people
- Westmead HospitalWestmead, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- ViroMissile, Inc.
- Trial code
- NCT06910657
- Record updated
- 5 August 2026
- Original description
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight the tumor.Read full original descriptionShow less
A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight the tumor.
The purpose of this study is to determine the safety of IDOV-Immune, how well it is tolerated, and to identify the highest dose that can be safely given. Researchers will also study how the drug behaves in the body, how the immune system responds to it, and whether it shows any signs of shrinking tumors.
Participants will receive a single intravenous (IV) infusion of IDOV-Immune and will be closely monitored for side effects and any changes in their cancer.
This study is being conducted at multiple sites in the United States and Australia.
Inclusion: Age ≥ 18 years; Histologically or cytologically confirmed advanced solid tumors that have progressed despite standard therapy, or for which no standard therapy exists; ECOG performance status ≤ 1; Measurable disease per RECIST v1.1; Adequate organ and bone marrow function; At least 28 days since major surgery, prior immunotherapy, or radiotherapy (with exceptions for minor procedures); Negative pregnancy test for women of childbearing potential; Agreement to use effective contraception during treatment and for 3 months after; Ability to provide informed consent and comply with study requirements.
Exclusion: Prior treatment with an oncolytic virus; Unresolved ≥ Grade 2 toxicities from prior therapies (except hair loss or stable chronic conditions); Interstitial lung disease or prior pneumonitis requiring steroids; Active or recent vaccinia virus infection or smallpox/monkeypox vaccination within 10 years; Active uncontrolled infection requiring systemic treatment; History of hepatitis B, hepatitis C, or HIV (unless meeting protocol-specific criteria); Active or symptomatic autoimmune disease requiring systemic therapy; Significant cardiac disease (e.g., NYHA Class III/IV heart failure); Conditions requiring chronic immunosuppressive therapy; Severe skin disorders or history of pancreatitis; Bleeding disorders or history of recent serious thromboembolic events; Any medical or psychiatric condition that could interfere with study participation; Active or untreated CNS metastases (unless stable per protocol).